CD161+CD127+CD8+ T cell subsets can predict the efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer with diabetes mellitus

The role of CD161+CD127+CD8+ T cells in non-small cell lung cancer (NSCLC) patients with diabetes remains unexplored. This study determined the prevalence, phenotype, and function of CD8+ T cell subsets in NSCLC with diabetes. We recruited NSCLC patients (n = 436) treated with anti-PD-1 immunotherap...

Descrición completa

Detalles Bibliográficos

Principais autores:	Jingjing Qu, Yuekang Li, Binggen Wu, Qian Shen, Lijun Chen, Wenjia Sun, Bo Wang, Lixiong Ying, Li Wu, Hong Zhou, Jianya Zhou, Jianying Zhou
Formato:	Artigo
Idioma:	Inglês
Publicado:	Taylor & Francis Group 2024-12-01
Series:	OncoImmunology
Assuntos:	CD161+CD127+CD8+ T cells diabetes mellitus immunotherapy non-small cell lung cancer predictive biomarkers
Acceso en liña:	https://www.tandfonline.com/doi/10.1080/2162402X.2024.2371575
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!